Clinical Trial Update: Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients

View source ↗

Summary

This registry study assesses clinical outcomes and safety of canakinumab (Ilaris) in patients with cryopyrin-associated periodic syndromes (CAPS). It covers fam…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cryopyrin-associated Periodic Syndromes
• Familial Cold Autoinflammatory Syndrome
• Muckle-wells Syndrome
• Neonatal-onset Multisystem Inflammatory Disease

Drugs mentioned

• ILARIS (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cryopyrin-associated Periodic Syndromes (CAPS), Familial Cold Autoinflam Syn (FCAS) | Status: COMPLETED